A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

Also called NCT02091362

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose basic science
Phase
Phase 2
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02091362
  • EudraCT 2013-003834-33
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Mexico, Poland, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02091362. Randomized; triple masking; primary purpose basic science. Start 2014-03 (registry gives no type); primary completion 2015-01 (actual). Results posted on 2018-07-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY2409021
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02091362
Content hash
f8c58771b48483492def749392a9070c1682c7cfdf645decffb186e9a01508a4